Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema (GlobeNewswire) - Apr 10, 2025 - "Oculis Holding...today announced that it has completed enrollment in both Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME, designed as pivotal registration studies to support global marketing applications including NDA submission and approval by the U.S. Food and Drug Administration (FDA)....Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter."
Enrollment closed • P3 data • Diabetic Macular Edema
|